Skip to Main Content

As the Trump administration labors to execute its blueprint for tackling high drug costs, a group of Democratic lawmakers introduced a bill on Wednesday that would allow the federal government to negotiate on behalf of Medicare — and authorize licenses for lower-cost generics when talks fail.

Unlike other bills that would permit negotiations over Part D drugs, the legislation would allow the Department of Health and Human Services to pursue a generic alternative by issuing a competitive license when a company refuses to offer a reasonable price. In effect, the bill would create a new mechanism for the U.S. government to sidestep patents when it would be in the public interest to do so.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!